Enzolytics Inc. (ENZC)
OTC PINK OTC PINK Primary Summary
ENZC Chart
Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT ALLEN, TX / ACCESSWIRE / September 18, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, represented by Professor Tchorbanov PhD, Head of the Department of Immunology and Penka Petrova PHD, DSc, Director of the Institute of Microbiology, has issued its first report under the recently announced collaborative agreement executed on September 9, 2024. The purpose of the study, which was sponsored by Rosetta, LLC, was to ascertain any pathological deviations as a result of the use of ENZC's exclusively licensed experimental cancer lyophilized pepsin treatment's key active ingredient, Irreversible Pepsin Fraction ("IPF"), on the Kidney, Liver, Lymph Nodes and Spleen, measure the increased activation of the immune system, determine any side effects from the use of the compound and establish survivability of the animals (mouse model on Balb/c inbred mouse line under specific pathogen free sterile conditions) used in the study.
Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
ALLEN, TX / ACCESSWIRE / September 9, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (" enzolytics.com ") (the "Company") announced today that the Company and the Stephan Angeloff Institute of Microbiology, Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, represented by Professor Tchorbanov PhD, Head of the Department of Immunology and Penka Petrova PHD, DSc, Director of the Institute of Microbiology, entered into a three year agreement to combine their efforts to accelerate discovery of combined applications and commercialization of their individual entity technologies. The initial focus will be combining Monoclonal Antibodies and Immune Therapeutic Proteins ("ITP") for the development of treatments of malignant antigens.
Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
ALLEN, TX / ACCESSWIRE / August 20, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that a study conducted at the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria concluded that inventor Harry Zhabilov's patented experimental cancer lyophilized pepsin treatment, exclusively licensed to Enzolytics, is effective in decreasing the growth and spread of cancer cells in breast cancer, colon cancer, prostate cancer, cancer of the larynx, as well as small cell lung cancer. The Conclusion of the report by Associate Professor Petya Genova-Kalu and Professor Dr. Iva Hristova, in its entirety reads as follows: "A polypeptide complex of lyophilized pepsin, causes cytopathological changes and significantly reduces the survival and/or proliferative activity of the cell cultures used as experimental models.
Enzolytics Inc. Dividends
| ENZC 23 May 2012 | Other | $150 Per Share |
Enzolytics Inc. Earnings
| 31 Dec 2016 Date | | - Cons. EPS | - EPS |
| 30 Sep 2016 Date | | - Cons. EPS | - EPS |
| 30 Jun 2016 Date | | - Cons. EPS | - EPS |
| 31 Mar 2016 Date | | - Cons. EPS | - EPS |
| 31 Dec 2015 Date | | - Cons. EPS | - EPS |
| ENZC 23 May 2012 | Other | $150 Per Share |
| 31 Dec 2016 Date | | - Cons. EPS | - EPS |
| 30 Sep 2016 Date | | - Cons. EPS | - EPS |
| 30 Jun 2016 Date | | - Cons. EPS | - EPS |
| 31 Mar 2016 Date | | - Cons. EPS | - EPS |
| 31 Dec 2015 Date | | - Cons. EPS | - EPS |
Enzolytics Inc. (ENZC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Enzolytics Inc. ever had a stock split?
Enzolytics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Steven Sharabura CEO | OTC PINK Exchange | 294112107 Cusip |
| US Country | 1 Employees | - Last Dividend | 7 Feb 2013 Last Split | - IPO Date |
Overview
Enzolytics Inc. is a pioneering drug development company based in Plano, Texas, dedicated to the commercialization of its innovative therapeutic proteins designed to combat debilitating infectious diseases. The company stands at the forefront of addressing some of the most critical healthcare challenges by focusing on the development of treatments for diseases such as HIV. Leveraging proprietary technologies and scientific expertise, Enzolytics Inc. aims to improve the lives of patients suffering from infectious diseases through non-toxic passive immunotherapy solutions.
Products and Services
- Patented Anti-HIV Therapeutics:
Enzolytics Inc. has developed patented therapeutics aimed at the effective treatment of HIV. These therapeutics have undergone clinical testing, demonstrating the company's commitment to advancing healthcare solutions for HIV-infected patients. The focus on anti-HIV therapeutics reflects the company's specialized expertise in targeting and neutralizing this virus, aiming to provide effective and less toxic treatment options.
- Proprietary Methodology for Producing Human IgG1 Monoclonal Antibodies:
The company employs a proprietary methodology for the production of human IgG1 monoclonal antibodies. These antibodies are specifically designed to target and neutralize infectious diseases, including HIV. This innovative approach to passive immunotherapy represents a significant advancement in the treatment of infectious diseases, offering potential for higher efficacy and safety compared to conventional treatment methods.
- Proprietary Cell Line for Antibody Production:
Enzolytics Inc. has developed a proprietary cell line that is instrumental in producing human monoclonal antibodies. These antibodies are tailored to target and neutralize the HIV virus effectively. The development of this cell line underscores the company's capabilities in biotechnological innovation and its commitment to creating targeted therapies for infectious diseases.
Contact Information
